InSilico Medicine Cayman TopCo (O15)
XDUS
5.05
+0.71 (+16.36%)
Real-time Data
06:00 AM
Day's Range
4.885.10
52 wk Range
3.529.04
Financial Statements - O15 - InSilico Medicine Cayman TopCo
Revenue
56.23M▼ 34.5%
Net Income
-352.31M▼ 1960.8%Net Margin -626.5%
EBITDA
-348.73M▼ 2968.5%
Free Cash Flow
-79.74M▼ 36.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Sales | 56.23M | 85.83M | 51.18M | 30.14M |
| Cost of Goods | 10.39M | 8.25M | 12.61M | 11.03M |
| Gross Profit | 45.84M | 77.57M | 38.56M | 19.11M |
 Operating Expense | - | - | - | - |
| Operating Income | -62.04M | -33.39M | -89.89M | -79.82M |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | - | - | - | - |
| Pre Tax Income | -352.25M | -16.93M | -211.55M | -221.81M |
| Income Tax | 60K | 161K | 84K | 13K |
| Net Income | -352.31M | -17.09M | -211.64M | -221.82M |
| EPS Basic | -4.48 | -0.03067 | -0.379679 | -0.397956 |
| EPS Diluted | -4.48 | -0.03067 | -0.379679 | -0.397956 |
| Basic Shares Outstanding | 78.70M | 557.41M | 557.41M | 557.41M |
| Diluted Shares Outstanding | 78.70M | 557.41M | 557.41M | 557.41M |
| Ebit | -352.04M | -16.84M | -211.46M | -221.71M |
| Ebitda | -348.73M | -11.36M | -207.58M | -78.37M |
| Net Income Continuous Operations | -352.31M | -17.09M | -211.64M | -221.82M |
| Minority Interests | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
